Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol

Maria C Katapodi, Valeria Viassolo, Maria Caiata-Zufferey, Christos Nikolaidis, Rosmarie Bührer-Landolt, Nicole Buerki, Rossella Graffeo, Henrik Csaba Horváth, Christian Kurzeder, Manuela Rabaglio, Michael Scharfe, Corinne Urech, Tobias E Erlanger, Nicole Probst-Hensch, Karl Heinimann, Viola Heinzelmann-Schwarz, Olivia Pagani, Pierre O Chappuis, Maria C Katapodi, Valeria Viassolo, Maria Caiata-Zufferey, Christos Nikolaidis, Rosmarie Bührer-Landolt, Nicole Buerki, Rossella Graffeo, Henrik Csaba Horváth, Christian Kurzeder, Manuela Rabaglio, Michael Scharfe, Corinne Urech, Tobias E Erlanger, Nicole Probst-Hensch, Karl Heinimann, Viola Heinzelmann-Schwarz, Olivia Pagani, Pierre O Chappuis

Abstract

Background: Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly diagnosed cancer cases in Switzerland, affecting more than 12,000 individuals annually. Hundreds of these patients are likely to carry germline pathogenic variants associated with hereditary breast ovarian cancer (HBOC) or Lynch syndrome (LS). Genetic services (counseling and testing) for hereditary susceptibility to cancer can prevent many cancer diagnoses and deaths through early identification and risk management.

Objective: Cascade screening is the systematic identification and testing of relatives of a known mutation carrier. It determines whether asymptomatic relatives also carry the known variant, needing management options to reduce future harmful outcomes. Specific aims of the CASCADE study are to (1) survey index cases with HBOC or LS from clinic-based genetic testing records and determine their current cancer status and surveillance practices, needs for coordination of medical care, psychosocial needs, patient-provider and patient-family communication, quality of life, and willingness to serve as advocates for cancer genetic services to blood relatives, (2) survey first- and second-degree relatives and first-cousins identified from pedigrees or family history records of HBOC and LS index cases and determine their current cancer and mutation status, cancer surveillance practices, needs for coordination of medical care, barriers and facilitators to using cancer genetic services, psychosocial needs, patient-provider and patient-family communication, quality of life, and willingness to participate in a study designed to increase use of cancer genetic services, and (3) explore the influence of patient-provider communication about genetic cancer risk on patient-family communication and the acceptability of a family-based communication, coping, and decision support intervention with focus group(s) of mutation carriers and relatives.

Methods: CASCADE is a longitudinal study using surveys (online or paper/pencil) and focus groups, designed to elicit factors that enhance cascade genetic testing for HBOC and LS in Switzerland. Repeated observations are the optimal way for assessing these outcomes. Focus groups will examine barriers in patient-provider and patient-family communication, and the acceptability of a family-based communication, coping, and decision-support intervention. The survey will be developed in English, translated into three languages (German, French, and Italian), and back-translated into English, except for scales with validated versions in these languages.

Results: Descriptive analyses will include calculating means, standard deviations, frequencies, and percentages of variables and participant descriptors. Bivariate analyses (Pearson correlations, chi-square test for differences in proportions, and t test for differences in means) will assess associations between demographics and clinical characteristics. Regression analyses will incorporate generalized estimating equations for pairing index cases with their relatives and explore whether predictors are in direct, mediating, or moderating relationship to an outcome. Focus group data will be transcribed verbatim and analyzed for common themes.

Conclusions: Robust evidence from basic science and descriptive population-based studies in Switzerland support the necessity of cascade screening for genetic predisposition to HBOC and LS. CASCADE is designed to address translation of this knowledge into public health interventions.

Trial registration: ClinicalTrials.gov NCT03124212; https://ichgcp.net/clinical-trials-registry/NCT03124212 (Archived by WebCite at http://www.webcitation.org/6tKZnNDBt).

Keywords: cancer surveillance; family communication; family-based interventions; patient-provider communication; psychosocial support; public health genetics; public health interventions; quality of life.

Conflict of interest statement

Conflicts of Interest: None declared.

©Maria C Katapodi, Valeria Viassolo, Maria Caiata-Zufferey, Christos Nikolaidis, Rosmarie Bührer-Landolt, Nicole Buerki, Rossella Graffeo, Henrik Csaba Horváth, Christian Kurzeder, Manuela Rabaglio, Michael Scharfe, Corinne Urech, Tobias E Erlanger, Nicole Probst-Hensch, Karl Heinimann, Viola Heinzelmann-Schwarz, Olivia Pagani, Pierre O. Chappuis. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 20.09.2017.

Figures

Figure 1
Figure 1
Expected recruitment of index cases.

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 01;136(5):E359–386. doi: 10.1002/ijc.29210. doi: 10.1002/ijc.29210.
    1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo ESG, Chen W, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2) Lancet. 2015 Mar 14;385(9972):977–1010. doi: 10.1016/S0140-6736(14)62038-9.
    1. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi O, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003 May;72(5):1117–1130. doi: 10.1086/375033.
    1. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King M, Swisher EM. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011 Nov 01;108(44):18032–18037. doi: 10.1073/pnas.1115052108.
    1. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science. 2014 Mar 28;343(6178):1466–1470. doi: 10.1126/science.1251827.
    1. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF, EMBRACE Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013 Jun 05;105(11):812–822. doi: 10.1093/jnci/djt095.
    1. NCI SEER Data, 1973-2014, 1973-2014. 2017. May 17, [2017-05-17].
    1. Balmaña J, Díez O, Rubio IT, Cardoso F, ESMO Guidelines Working Group BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2011 Sep;22 Suppl 6:vi31–34. doi: 10.1093/annonc/mdr373.
    1. Christinat A, Pagani O. Practical aspects of genetic counseling in breast cancer: lights and shadows. Breast. 2013 Aug;22(4):375–382. doi: 10.1016/j.breast.2013.04.006.
    1. Anglian Breast Cancer Study Group Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2000 Nov;83(10):1301–1308. doi: 10.1054/bjoc.2000.1407. doi: 10.1054/bjoc.2000.1407.
    1. King M, Marks JH, Mandell JB, New York Breast Cancer Study Group Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003 Oct 24;302(5645):643–646. doi: 10.1126/science.1088759.
    1. Whittemore AS, Gong G, John EM, McGuire V, Li FP, Ostrow KL, Dicioccio R, Felberg A, West DW. Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2078–2083.
    1. Bouchardy C, Lorez M, Arndt V. Schweizer Krebsbulletin; 35 (Auflage 4200) 2015. Jun 15, [2017-08-31]. Effects of age and stage on breast cancer survival in Switzerland
    1. Schoumacher F, Glaus A, Mueller H, Eppenberger U, Bolliger B, Senn HJ. BRCA1/2 mutations in Swiss patients with familial or early-onset breast and ovarian cancer. Swiss Med Wkly. 2001 Apr 21;131(15-16):223–226.
    1. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, Levin TR, Lieberman DA, Robertson DJ, Syngal S, Rex DK. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol. 2014 Aug;109(8):1159–1179. doi: 10.1038/ajg.2014.186.
    1. Bonis P, Trikalinos T, Chung M, Chew P, Ip S, DeVine D, Lau J. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evid Rep Technol Assess (Full Rep) 2007 May;(150):1–180.
    1. Bellcross CA, Bedrosian SR, Daniels E, Duquette D, Hampel H, Jasperson K, Joseph DA, Kaye C, Lubin I, Meyer LJ, Reyes M, Scheuner MT, Schully SD, Senter L, Stewart SL, St PJ, Westman J, Wise P, Yang VW, Khoury MJ. Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genet Med. 2012 Jan;14(1):152–162. doi: 10.1038/gim.0b013e31823375ea.
    1. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, American COG. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015 Feb;110(2):223–262; quiz 263. doi: 10.1038/ajg.2014.435.
    1. US Preventive Services Task Force. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, García FAR, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016 Jun 21;315(23):2564–2575. doi: 10.1001/jama.2016.5989.
    1. Kladny J, Lubinski J. Lynch syndrome (HNPCC) Hered Cancer Clin Pract. 2008 Jun 15;6(2):99–102. doi: 10.1186/1897-4287-6-2-99.
    1. Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer. 2015 Dec;15(3):181–194. doi: 10.1038/nrc3878.
    1. Umar A, Boland CR, Terdiman JP, Syngal S, de LCA, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HFA, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004 Feb 18;96(4):261–268.
    1. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009 Jan;11(1):42–65. doi: 10.1097/GIM.0b013e31818fa2db.
    1. Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, Watson P, Gruber SB, Euhus D, Kinzler KW, Jass J, Gallinger S, Lindor NM, Casey G, Ellis N, Giardiello FM, Offit K, Parmigiani G, Colon Cancer Family Registry Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA. 2006 Sep 27;296(12):1479–1487. doi: 10.1001/jama.296.12.1479.
    1. Kalady MF, Heald B. Diagnostic Approach to Hereditary Colorectal Cancer Syndromes. Clin Colon Rectal Surg. 2015 Dec;28(4):205–214. doi: 10.1055/s-0035-1564432.
    1. Lynch JA, Venne V, Berse B. Genetic tests to identify risk for breast cancer. Semin Oncol Nurs. 2015 May;31(2):100–107. doi: 10.1016/j.soncn.2015.02.007.
    1. Douma KFL, Meiser B, Kirk J, Mitchell G, Saunders C, Rahman B, Sousa MS, Barlow-Stewart K, Gleeson M, Tucker K. Health professionals' evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer. Fam Cancer. 2015 Jun;14(2):265–272. doi: 10.1007/s10689-014-9770-z.
    1. Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol. 2015 Sep;33(9):900–902. doi: 10.1038/nbt.3322.
    1. Ayme A, Viassolo V, Rapiti E, Fioretta G, Schubert H, Bouchardy C, Chappuis PO, Benhamou S. Determinants of genetic counseling uptake and its impact on breast cancer outcome: a population-based study. Breast Cancer Res Treat. 2014 Apr;144(2):379–389. doi: 10.1007/s10549-014-2864-3.
    1. Schmeler KM, Lynch HT, Chen L, Munsell MF, Soliman PT, Clark MB, Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006 Jan 19;354(3):261–269. doi: 10.1056/NEJMoa052627.
    1. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011 Sep 01;117(17):3900–7. doi: 10.1002/cncr.25971. doi: 10.1002/cncr.25971.
    1. Caiata-Zufferey M. Genetically at-risk status and individual agency. A qualitative study on asymptomatic women living with genetic risk of breast/ovarian cancer. Soc Sci Med. 2015 May;132:141–148. doi: 10.1016/j.socscimed.2015.03.037.
    1. Caiata-Zufferey M, Pagani O, Cina V, Membrez V, Taborelli M, Unger S, Murphy A, Monnerat C, Chappuis PO. Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations. Genet Med. 2015 Sep;17(9):726–732. doi: 10.1038/gim.2014.183.
    1. Howell D, Hack TF, Oliver TK, Chulak T, Mayo S, Aubin M, Chasen M, Earle CC, Friedman AJ, Green E, Jones GW, Jones JM, Parkinson M, Payeur N, Sabiston CM, Sinclair S. Models of care for post-treatment follow-up of adult cancer survivors: a systematic review and quality appraisal of the evidence. J Cancer Surviv. 2012 Dec;6(4):359–371. doi: 10.1007/s11764-012-0232-z.
    1. IOM . Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. Washington, DC: National Academies Press; 2013. [2017-09-07]. .
    1. Blandy C, Chabal F, Stoppa-Lyonnet D, Julian-Reynier C. Testing participation in BRCA1/2-positive families: initiator role of index cases. Genet Test. 2003;7(3):225–233. doi: 10.1089/109065703322537241.
    1. Suthers GK, Armstrong J, McCormack J, Trott D. Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder. J Med Genet. 2006 Aug;43(8):665–670. doi: 10.1136/jmg.2005.039172.
    1. Gurmankin AD, Domchek S, Stopfer J, Fels C, Armstrong K. Patients' resistance to risk information in genetic counseling for BRCA1/2. Arch Intern Med. 2005 Mar 14;165(5):523–529. doi: 10.1001/archinte.165.5.523.
    1. Tercyak KP, Demarco TA, Mars BD, Peshkin BN. Women's satisfaction with genetic counseling for hereditary breast-ovarian cancer: psychological aspects. Am J Med Genet A. 2004 Nov 15;131(1):36–41. doi: 10.1002/ajmg.a.30317.
    1. Federal Act on Human Genetic Testing. [2017-09-08]. .
    1. Dekker N, Hermens RPMG, Elwyn G, van DWT, Nagengast FM, van DP, Salemink S, Adang E, van KJHJM, Ligtenberg MJL, Hoogerbrugge N. Improving calculation, interpretation and communication of familial colorectal cancer risk: protocol for a randomized controlled trial. Implement Sci. 2010 Jan 28;5:6. doi: 10.1186/1748-5908-5-6.
    1. Graves K, Wenzel L, Schwartz M, Luta G, Wileyto P, Narod S, Peshkin B, Marcus A, Cella D, Emsbo S, Barnes D, Halbert C. Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):648–654. doi: 10.1158/1055-9965.EPI-09-0548.
    1. Green MJ, Peterson SK, Baker MW, Harper GR, Friedman LC, Rubinstein WS, Mauger DT. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. JAMA. 2004 Jul 28;292(4):442–452. doi: 10.1001/jama.292.4.442.
    1. Hooker GW, Leventhal K, DeMarco T, Peshkin BN, Finch C, Wahl E, Joines JR, Brown K, Valdimarsdottir H, Schwartz MD. Longitudinal changes in patient distress following interactive decision aid use among BRCA1/2 carriers: a randomized trial. Med Decis Making. 2011;31(3):412–421. doi: 10.1177/0272989X10381283.
    1. Joseph G, Beattie MS, Lee R, Braithwaite D, Wilcox C, Metrikin M, Lamvik K, Luce J. Pre-counseling Education for Low Literacy Women at Risk of Hereditary Breast and Ovarian Cancer (HBOC): Patient Experiences Using the Cancer Risk Education Intervention Tool (CREdIT) J Genet Counsel. 2010 May 19;19(5):447–462. doi: 10.1007/s10897-010-9303-3.
    1. Kaphingst KA, Persky S, McCall C, Lachance C, Loewenstein J, Beall AC, Blascovich J. Testing the effects of educational strategies on comprehension of a genomic concept using virtual reality technology. Patient Educ Couns. 2009 Nov;77(2):224–230. doi: 10.1016/j.pec.2009.03.029.
    1. Kardashian A, Fehniger J, Creasman J, Cheung E, Beattie MS. A Pilot study of the Sharing Risk Information Tool (ShaRIT) for Families with Hereditary Breast and Ovarian Cancer Syndrome. Hered Cancer Clin Pract. 2012 Apr 12;10(1):4. doi: 10.1186/1897-4287-10-4.
    1. Mancini J, Noguès C, Adenis C, Berthet P, Bonadona V, Chompret A, Coupier I, Eisinger F, Fricker J, Gauthier-Villars M, Lasset C, Lortholary A, N'Guyen TD, Vennin P, Sobol H, Stoppa-Lyonnet D, Julian-Reynier C. Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing. Eur J Cancer. 2006 May;42(7):871–881. doi: 10.1016/j.ejca.2005.10.029.
    1. Tiller K, Meiser B, Gaff C, Kirk J, Dudding T, Phillips K, Friedlander M, Tucker K. A randomized controlled trial of a decision aid for women at increased risk of ovarian cancer. Med Decis Making. 2006;26(4):360–372. doi: 10.1177/0272989X06290486.
    1. Wakefield CE, Meiser B, Homewood J, Peate M, Taylor A, Lobb E, Kirk J, Young M, Williams R, Dudding T, Tucker K, AGenDA Collaborative Group A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk. Breast Cancer Res Treat. 2008 Jan;107(2):289–301. doi: 10.1007/s10549-007-9539-2.
    1. Wang C, Gonzalez R, Milliron KJ, Strecher VJ, Merajver SD. Genetic counseling for BRCA1/2: a randomized controlled trial of two strategies to facilitate the education and counseling process. Am J Med Genet A. 2005 Apr 01;134A(1):66–73. doi: 10.1002/ajmg.a.30577.
    1. Grosse SD, Rogowski WH, Ross LF, Cornel MC, Dondorp WJ, Khoury MJ. Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. Public Health Genomics. 2010;13(2):106–115. doi: 10.1159/000226594.
    1. Hampel H. Genetic counseling and cascade genetic testing in Lynch syndrome. Fam Cancer. 2016 Jul;15(3):423–427. doi: 10.1007/s10689-016-9893-5.
    1. Khoury MJ, Evans JP. A public health perspective on a national precision medicine cohort: balancing long-term knowledge generation with early health benefit. JAMA. 2015 Jun 02;313(21):2117–2118. doi: 10.1001/jama.2015.3382.
    1. Galema-Boers JMH, Versmissen J, Roeters VLHWO, Dusault-Wijkstra JE, Williams M, Roeters VLJE. Cascade screening of familial hypercholesterolemia must go on. Atherosclerosis. 2015 Oct;242(2):415–417. doi: 10.1016/j.atherosclerosis.2015.07.020.
    1. Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de HJA, Domchek SM, Drapkin R, Spencer FH, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, Swisher EM, Takenaka M, Bowtell DD, Sherman ME. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. J Clin Oncol. 2017 Jul 10;35(20):2329–2337. doi: 10.1200/JCO.2016.70.3439.
    1. Bouchardy C, Benhamou S, Fioretta G, Verkooijen HM, Chappuis PO, Neyroud-Caspar I, Castiglione M, Vinh-Hung V, Vlastos G, Rapiti E. Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat. 2011 May;127(1):233–241. doi: 10.1007/s10549-010-1137-z.
    1. Buehler Michelle, Tse Brian, Leboucq Alix, Jacob Francis, Caduff Rosmarie, Fink Daniel, Goldstein Darlene R, Heinzelmann-Schwarz Viola. Meta-analysis of microarray data identifies GAS6 expression as an independent predictor of poor survival in ovarian cancer. Biomed Res Int. 2013;2013:238284. doi: 10.1155/2013/238284. doi: 10.1155/2013/238284.
    1. Decollogne S, Joshi S, Chung SA, Luk PP, Yeo RX, Nixdorf S, Fedier A, Heinzelmann-Schwarz V, Hogg PJ, Dilda PJ. Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells. Gynecol Oncol. 2015 Aug;138(2):363–371. doi: 10.1016/j.ygyno.2015.06.018.
    1. Genevay M, Benusiglio PR, Hutter P, Chappuis PO. [Lynch syndrome: when pathologist and clinician have the opportunity to reduce the risk of developing cancer] Rev Med Suisse. 2011 Jul 27;7(303):1502–1506.
    1. Heinimann K. Toward a molecular classification of colorectal cancer: the role of microsatellite instability status. Front Oncol. 2013 Oct 31;3:272. doi: 10.3389/fonc.2013.00272. doi: 10.3389/fonc.2013.00272.
    1. Henry C, Llamosas E, Knipprath-Meszaros A, Schoetzau A, Obermann E, Fuenfschilling M, Caduff R, Fink D, Hacker N, Ward R, Heinzelmann-Schwarz V, Ford C. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. Oncotarget. 2015 Nov 24;6(37):40310–40326. doi: 10.18632/oncotarget.5643.
    1. Kempers MJE, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, Schackert HK, Steinke V, Holinski-Feder E, Morak M, Kloor M, Büttner R, Verwiel ETP, van KJH, Nagtegaal ID, Goossens M, van DPRS, Niessen RC, Sijmons RH, Kluijt I, Hogervorst FBL, Leter EM, Gille JJP, Aalfs CM, Redeker EJW, Hes FJ, Tops CMJ, van NBPM, van GME, Gómez GEB, Eccles DM, Bunyan DJ, Syngal S, Stoffel EM, Culver JO, Palomares MR, Graham T, Velsher L, Papp J, Oláh E, Chan TL, Leung SY, van KAG, Kiemeney LALM, Hoogerbrugge N, Ligtenberg MJL. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011 Jan;12(1):49–55. doi: 10.1016/S1470-2045(10)70265-5.
    1. Manegold-Brauer G, Bellin AK, Tercanli S, Lapaire O, Heinzelmann-Schwarz V. The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging. Arch Gynecol Obstet. 2014 Mar;289(3):491–498. doi: 10.1007/s00404-013-3081-8.
    1. Schwab FD, Bürki N, Huang DJ, Heinzelmann-Schwarz V, Schmid SM, Vetter M, Schötzau A, Güth U. Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer. Fam Cancer. 2014 Mar;13(1):99–107. doi: 10.1007/s10689-013-9682-3.
    1. Vasen HFA, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin J, Møller Pal, Myrhoj T, Nagengast FM, Parc Y, Ponz DLM, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJW, Rahner N, Wijnen JT, Järvinen HJ, Möslein G, Mallorca Group Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013 Jun;62(6):812–823. doi: 10.1136/gutjnl-2012-304356.
    1. Verkooijen HM, Rapiti E, Fioretta G, Vinh-Hung V, Keller J, Benhamou S, Vlastos G, Chappuis PO, Bouchardy C. Impact of a positive family history on diagnosis, management, and survival of breast cancer: different effects across socio-economic groups. Cancer Causes Control. 2009 Nov;20(9):1689–1696. doi: 10.1007/s10552-009-9420-1.
    1. Eysenbach G, CONSORT-EHEALTH Group CONSORT-EHEALTH: improving and standardizing evaluation reports of Web-based and mobile health interventions. J Med Internet Res. 2011 Dec 31;13(4):e126. doi: 10.2196/jmir.1923.
    1. Katapodi MC, Duquette D, Yang JJ, Mendelsohn-Victor K, Anderson B, Nikolaidis C, Mancewicz E, Northouse LL, Duffy S, Ronis D, Milliron KJ, Probst-Herbst N, Merajver SD, Janz NK, Copeland G, Roberts S. Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study. Cancer Causes Control. 2017 Mar;28(3):191–201. doi: 10.1007/s10552-017-0858-2.
    1. Katapodi MC, Northouse LL, Milliron KJ, Liu G, Merajver SD. Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families. Psychooncology. 2013 Jun;22(6):1336–1343. doi: 10.1002/pon.3139.
    1. Caiata-Zufferey M, Schulz PJ. Physicians' communicative strategies in interacting with Internet-informed patients: results from a qualitative study. Health Commun. 2012;27(8):738–749. doi: 10.1080/10410236.2011.636478.
    1. Morgan D, Krueger R, King J. Focus Group Kit. Thousand Oaks, CA: SAGE Publications; 1998.
    1. Katapodi Mc, Northouse Ll, Schafenacker Am, Duquette D, Duffy Sa, Ronis Dl, Anderson B, Janz Nk, McLosky J, Milliron Kj, Merajver Sd, Duong Lm, Copeland G. Using a state cancer registry to recruit young breast cancer survivors and high-risk relatives: protocol of a randomized trial testing the efficacy of a targeted versus a tailored intervention to increase breast cancer screening. BMC Cancer. 2013 Mar 1;13(1):e1001940. doi: 10.1186/1471-2407-13-97.
    1. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989 Dec 20;81(24):1879–1886.
    1. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001 Mar 07;93(5):358–366.
    1. Michigan Department of Health and Human Services BRFS annual questionnaires. 2017. [2017-08-31]. .
    1. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016 Feb 20;34(6):611–635. doi: 10.1200/JCO.2015.64.3809.
    1. Vickberg SMJ. The Concerns About Recurrence Scale (CARS): a systematic measure of women's fears about the possibility of breast cancer recurrence. Ann Behav Med. 2003;25(1):16–24.
    1. Katapodi M, Jung M, Milliron K, Merajver S, Northouse L. Psychological distress of developing hereditary breast/ovarian cancer among female relatives who did not pursue BRCA1 or BRCA2 genetic testing. 11th International Conference on Psychosocial Aspects of Genetic Testing for Hereditary Cancer; April 5, 2009; Toronto, ON. 2009. pp. 23–2.
    1. Katapodi MC, Munro ML, Pierce PF, Williams RA. Psychometric testing of the decisional conflict scale: genetic testing hereditary breast and ovarian cancer. Nurs Res. 2011;60(6):368–377. doi: 10.1097/NNR.0b013e3182337dad.
    1. Brehaut JC, O'Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, Feldman-Stewart D. Validation of a decision regret scale. Med Decis Making. 2003;23(4):281–292. doi: 10.1177/0272989X03256005.
    1. Carver CS. You want to measure coping but your protocol's too long: consider the brief COPE. Int J Behav Med. 1997;4(1):92–100. doi: 10.1207/s15327558ijbm0401_6.
    1. Bandura A. Human agency in social cognitive theory. Am Psychol. 1989 Sep;44(9):1175–1184.
    1. Katapodi MC, Aouizerat BE. Do women in the community recognize hereditary and sporadic breast cancer risk factors? Oncol Nurs Forum. 2005 May 10;32(3):617–623. doi: 10.1188/05.ONF.617-623.
    1. Katapodi MC, DeFlon SL, Milliron KJ, Northouse LL, Merajver S. Knowledge of risk factors and modes of gene transmission among women at risk for hereditary breast and ovarian cancer syndrome. JCO. 2011 May 20;29(15_suppl):e12017. doi: 10.1200/jco.2011.29.15_suppl.e12017.
    1. Lewis FM, Hammond MA, Woods NF. The family's functioning with newly diagnosed breast cancer in the mother: the development of an explanatory model. J Behav Med. 1993 Aug;16(4):351–370.
    1. Katapodi MC, Facione NC, Miaskowski C, Dodd MJ, Waters C. The influence of social support on breast cancer screening in a multicultural community sample. Oncol Nurs Forum. 2002 Jun;29(5):845–852. doi: 10.1188/02.ONF.845-852.
    1. Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G. Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors. J Cancer Epidemiol. 2012;2012:298745. doi: 10.1155/2012/298745. doi: 10.1155/2012/298745.
    1. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220–233.
    1. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006 Jan;3(2):77–101. doi: 10.1191/1478088706qp063oa.
    1. Khoury MJ, Iademarco MF, Riley WT. Precision Public Health for the Era of Precision Medicine. Am J Prev Med. 2016 Mar;50(3):398–401. doi: 10.1016/j.amepre.2015.08.031.
    1. Ademi Z, Watts GF, Pang J, Sijbrands EJG, van Bockxmeer FM, O'Leary P, Geelhoed E, Liew D. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol. 2014;8(4):390–400. doi: 10.1016/j.jacl.2014.05.008.
    1. Sie AS, Mensenkamp AR, Adang EMM, Ligtenberg MJL, Hoogerbrugge N. Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. Ann Oncol. 2014 Oct;25(10):2001–2007. doi: 10.1093/annonc/mdu361.
    1. Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technol Assess. 2014 Sep;18(58):1–406. doi: 10.3310/hta18580. doi: 10.3310/hta18580.
    1. Ned RM, Sijbrands EJG. Cascade Screening for Familial Hypercholesterolemia (FH) PLoS Curr. 2011 May 23;3:RRN1238. doi: 10.1371/currents.RRN1238. doi: 10.1371/currents.RRN1238.
    1. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJG, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJP, International FH Foundation Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation: executive summary. J Atheroscler Thromb. 2014;21(4):368–374.
    1. Datta BN, McDowell IFW, Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol. 2010 Aug;21(4):366–371. doi: 10.1097/MOL.0b013e32833c14e2.
    1. Finnie Rm. Cascade screening for familial hypercholesterolaemia in Scotland. The British Journal of Diabetes & Vascular Disease. 2010 Jun 21;10(3):123–125. doi: 10.1177/1474651409343245.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera